{
    "clinical_study": {
        "@rank": "4690", 
        "arm_group": [
            {
                "arm_group_label": "BIA 2-093", 
                "arm_group_type": "Experimental", 
                "description": "According to randomisation, subjects were to receive BIA 2-093 450 mg bid, BIA 2-093 900 mg od, or Trileptal\u00ae 450 mg bid on each of the 3 periods"
            }, 
            {
                "arm_group_label": "Oxcarbazepine", 
                "arm_group_type": "Active Comparator", 
                "description": "According to randomisation, subjects were to receive BIA 2-093 450 mg bid, BIA 2-093 900 mg od, or Trileptal\u00ae 450 mg bid on each of the 3 periods"
            }
        ], 
        "brief_summary": {
            "textblock": "To investigate the steady-state pharmacokinetics of once-daily and twice-daily regimens of\n      BIA 2-093 and twice-daily regimen of Oxcarbazepine (Trileptal\u00ae) in healthy subjects and to\n      assess the tolerability of such regimens in healthy subjects."
        }, 
        "brief_title": "Steady-state Pharmacokinetics of BIA 2-093 and Oxcarbazepine in Healthy Volunteers", 
        "completion_date": {
            "#text": "December 2003", 
            "@type": "Actual"
        }, 
        "condition": "Epilepsy", 
        "condition_browse": {
            "mesh_term": "Epilepsy"
        }, 
        "detailed_description": {
            "textblock": "Single centre, open-label, randomised, three-way crossover study in 12 healthy volunteers.\n      The study consisted of three 8-day treatment periods separated by washout periods of 10-15\n      days. On each of the treatment periods the volunteers received either a daily oral dose of\n      BIA 2-093 900 mg once-daily (od), BIA 2-093 450 mg twice-daily (bid), or Oxcarbazepine\n      (Trileptal\u00ae) 450 mg bid."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects were eligible for entry into the study if they fulfilled the following\n             inclusion criteria:\n\n          -  Male or female subjects aged between 18 and 45 years, inclusive.\n\n          -  Subjects of body mass index (BMI) between 19 and 28 kg/m2, inclusive.\n\n          -  Subjects who were healthy as determined by pre-study medical history, physical\n             examination, neurological examination, and 12-lead ECG.\n\n          -  Subjects who had clinical laboratory tests clinically acceptable.\n\n          -  Subjects who were negative for HBsAg, anti-HCV Ab and HIV-1 and HIV-2 Ab tests at\n             screening.\n\n          -  Subjects who were negative for alcohol and drugs of abuse at screening and first\n             admission.\n\n          -  Subjects who were non-smokers or who smoked less than 10 cigarettes or equivalent per\n             day.\n\n          -  Subjects who were able and willing to give written informed consent.\n\n          -  If case of female subjects, subjects who were not of childbearing potential by reason\n             of surgery or, if of childbearing potential, who used one of the following methods of\n             contraception: double-barrier, intrauterine device or abstinence.\n\n          -  If case of female subjects, subjects who had a negative pregnancy test at screening\n             and first admission.\n\n        Exclusion Criteria:\n\n          -  Subjects who did not conform to the above inclusion criteria.\n\n          -  Subjects who had a clinically relevant history or presence of respiratory,\n             gastrointestinal, renal, hepatic, haematological, lymphatic, neurological,\n             cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological,\n             dermatological, endocrine, connective tissue diseases or disorders.\n\n          -  Subjects who had a clinically relevant surgical history.\n\n          -  Subjects who had a clinically relevant family history.\n\n          -  Subjects who had a history of relevant atopy.\n\n          -  Subjects who had a history of hypersensitivity to carbamazepine or oxcarbazepine or\n             any other relevant drug hypersensitivity.\n\n          -  Subjects who had a history of alcoholism or drug abuse.\n\n          -  Subjects who consumed more than 14 units of alcohol a week.\n\n          -  Subjects who had a significant infection or known inflammatory process on screening\n             and/or first admission.\n\n          -  Subjects who had acute gastrointestinal symptoms at the time of screening and/or\n             first admission (e.g., nausea, vomiting, diarrhoea, heartburn).\n\n          -  Subjects who had used prescription or over-the-counter medication within two weeks of\n             first admission.\n\n          -  Subjects who had used any investigational drug and/or participated in any clinical\n             trial within four months of their first admission.\n\n          -  Subjects who had previously received BIA 2-093.\n\n          -  Subjects who had donated and/or received any blood or blood products within the\n             previous 4 months prior to screening.\n\n          -  Subjects who were vegetarians, vegans and/or have medical dietary restrictions.\n\n          -  Subjects who could not communicate reliably with the investigator.\n\n          -  Subjects who were unlikely to co-operate with the requirements of the study.\n\n          -  Subjects who were unwilling or unable to give written informed consent.\n\n          -  In case of female subjects, subjects who were pregnant or breast-feeding.\n\n          -  In case of female subjects, subjects who were of childbearing potential and did not\n             use an approved effective contraceptive method or used oral contraceptives."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "11", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 31, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01679002", 
            "org_study_id": "BIA-2093-110"
        }, 
        "intervention": [
            {
                "arm_group_label": "BIA 2-093", 
                "description": "Tablets containing BIA 2-093 450 mg", 
                "intervention_name": "BIA 2-093", 
                "intervention_type": "Drug", 
                "other_name": "Eslicarbazepine acetate"
            }, 
            {
                "arm_group_label": "Oxcarbazepine", 
                "description": "Trileptal\u00ae tablets containing 150 mg and 300 mg of Oxcarbazepine", 
                "intervention_name": "Oxcarbazepine", 
                "intervention_type": "Drug", 
                "other_name": "Trileptal\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Oxcarbazepine", 
                "Carbamazepine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Epilepsy", 
            "Oxcarbazepine", 
            "Eslicarbazepine Acetate", 
            "BIA 2-093"
        ], 
        "lastchanged_date": "August 31, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "S. Mamede do Coronado", 
                    "country": "Portugal", 
                    "state": "Trofa", 
                    "zip": "4745-457"
                }, 
                "name": "BIAL - Portela & C\u00aa S.A. - Human Pharmacology Unit (UFH)"
            }
        }, 
        "location_countries": {
            "country": "Portugal"
        }, 
        "number_of_arms": "2", 
        "official_title": "Steady-state Pharmacokinetics of BIA 2-093 and Oxcarbazepine in Healthy Volunteers", 
        "other_outcome": {
            "description": "Monitoring of Adverse Events throughout the study: Safety was evaluated from the number of reported adverse events (AEs) by patient", 
            "measure": "Number of adverse events reported per patient", 
            "safety_issue": "Yes", 
            "time_frame": "8 weeks"
        }, 
        "overall_official": {
            "affiliation": "BIAL - Portela & C\u00aa S.A.", 
            "last_name": "Manuel Vaz-da-Silva, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Portugal: National Pharmacy and Medicines Institute", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2003", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Pharmacokinetic parameters were derived from the concentration versus time profiles after each dose in each subject:time at which the Cmax occurred (tmax)", 
            "measure": "maximum observed plasma drug concentration (Cmax)", 
            "safety_issue": "No", 
            "time_frame": "pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72 and 96 h post-dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01679002"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Pharmacokinetic parameters were derived from the concentration versus time profiles after each dose in each subject: area under the plasma concentration versus time curve (AUC) to last measurable time point (AUC0-t)", 
            "measure": "area under the plasma concentration versus time curve (AUC)", 
            "safety_issue": "No", 
            "time_frame": "pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72 and 96 h post-dose"
        }, 
        "source": "Bial - Portela C S.A.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bial - Portela C S.A.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2003", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}